louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06243601: Effect of Aloe Vera Gel as an Intra Canal Medicament
Official title: Effect of Aloe Vera Gel as an Intra Canal Medicament in Patients With Asymptomatic Periapical Lesions.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Periapical Diseases
Keywords: Antibacterial, Analgesic, Clinical signs and symptoms
Lead sponsor: Islamabad Medical and Dental College
Sponsor class: OTHER
First posted: 2024-02-06
Enrollment: 60
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: This research will overview the effect of aloe vera gel (AVG) as intra canal medicament in patients with asymptomatic periapical lesions. It will provide endodontists with scientific evidence regarding the beneficial use of AVG as an intracanal medicament owing to its superior antibacterial and analgesic properties as compared to routinely used commercial intra canal medicaments.

Detailed description: Objective: To evaluate the effect of aloe vera gel based on clinical signs and symptoms as an intracanal medicament in asymptomatic periapical lesions over a period of three weeks. Methodology: Fresh AVG will be prepared. It will be placed as intracanal medicament after cleaning and shaping in patients with asymptomatic periapical lesions in group A while in group B (control group) no intracanal medicament will be placed. Patients will be randomly divided into two groups by randomization in Statistical Package for Social Sciences software (SPSS v24.0). They will be recalled for one week and three week follow ups and in case of no clinical signs and symptoms endodontic procedure will be completed. Statistical analysis: Descriptive statistics will be used for reporting age. Frequencies and percentages will be calculated for categorical variables and intergroup comparison will be done by chi square test

Eligibility criteria: Inclusion Criteria:

* Both male and female patients presenting with asymptomatic periapical lesions in permanent teeth

Exclusion Criteria:

* History of allergy to AVG

  * Comorbidities likely to impair healing
  * Pregnant women
  * History of previous endodontic treatment in the same tooth
  * Presence of pulp calcification
  * Internal or external root resorption

Primary outcomes:
measure: Presence or absence of signs and symptoms of the patient
timeFrame: One week and 3 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Islamabad
country: Pakistan
facility: Islamabad Dental Hospital
state: Federal
Study officials:
affiliation: Islamabad Dental Hospital
name: Saima Azam, BDS,FCPS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00561301: Biweekly Gemcitabine-Oxaliplatin and Dexamethasone for Relapsed/Refractory Malignant Lymphoma
Official title: Biweekly Gemcitabine-Oxaliplatin and Dexamethasone for Relapsed/Refractory Malignant Lymphoma
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Lymphoma
Lead sponsor: Cooperative Study Group A for Hematology
Sponsor class: NETWORK
First posted: 2007-11-20
Enrollment: 43
Sex: ALL
Minimum age (years): 15
Maximum age (years): 65
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: - To evaluate the feasibility of combination chemotherapies comprising of gemcitabine-dexamethasone-oxaliplatin for patients with refractory or relapsed malignant non-Hodgkin lymphoma (NHL)

Detailed description: - The feasibility will be evaluated in terms of objective response rate, efficacy of stem cell collection, disease-free survival, and overall survival.

Eligibility criteria: Inclusion Criteria:

* Patients who have refractory to first-line CHOP-like regimen
* Patients who have first relapse after
* first-line CHOP-like regimen
* upfront autologous or allogeneic hematopoietic stem cell transplantation
* Age 15 years or more
* ECOG performance status ≤ 2
* Adequate bone marrow function
* Adequate kidney,liver,cardiac

Exclusion Criteria:

* Patients who have received GEM or OX

Primary outcomes:
measure: objective response rate
timeFrame: 10/2009
Secondary outcomes:
measure: toxicities, progression-free survival, overall survival, ASCC efficacy, rate for proceeding to ASCT
timeFrame: 10/2009
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Asan Medical Center
Study officials:
affiliation: Ulsan Universtity Hospital, ROK
name: Hawk Kim, professor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04320901: Energy Device Study in Transoral Endoscopic Thyroidectomy
Official title: Comparative Analysis Between Harmonic Versus LigaSure in Transoral Endoscopic Thyroidectomy: A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Thyroid Nodule
Thyroid Cancer
Lead sponsor: Inha University Hospital
Sponsor class: OTHER
First posted: 2020-03-25
Enrollment: 40
Sex: ALL
Minimum age (years): 20
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Open label randomized controlled study, for Harmonic versus Ligasure in transoral endoscopic thyroid surgery.

Detailed description: * This is a prospective randomized controlled study. The principal investigator or another clinical investigator in charge will individually inform the patients about the study, on the day before surgery.
* When informed consent is obtained, an investigator in charge of randomization only, will randomize the patients.
* According to randomization, the experimental group will Ligasure and the control group will use Harmonic ACE 7+. Other than the randomized use of energy devices, the protocol for TOETVA is performed as usual.
* Operation time (from insertion of the laparoscopic camera to removal of the camera), number of times the camera was cleaned, intraoperative blood loss will recorded.
* Postoperative hospital stay, visual analog pain scale, blood cell count and inflammatory parameters, postoperative drain amount will recorded.
* Complications of thyroid surgery (vocal cord dysfunction, hypoparathyroidism) are compared for safety assessment.

Eligibility criteria: Inclusion Criteria:

* Patients who planned to transoral endoscopic thyroidectomy
* Age between 20 to 70
* Voluntarily consenting to the study and study agreement
* No local invasion or distant metastasis
* Normal vocal cord function in laryngoscopic exam
* No significant abnormalities in preoperative laboratory tests

Exclusion Criteria:

* Take aspirin or antiplatelet drugs within 7 days before admission
* Uncontrolled hypertension, diabetes, chronic renal failure, or coagulation disease
* History of cardiovascular disease (angina pectoris, heart failure, myocardial infarction, history of coronary artery disease, stroke, transient ischemic attack)
* Substance abuse and alcohol abuse
* History of esophageal and airway diseases
* Patient was participated in other clinical trials within 30 days
* History of neck irradiation or surgery
* History of severe drug allergies
* Pregnant or lactating women

Primary outcomes:
measure: Operation time
timeFrame: During the procedure
measure: Camera cleaning frequency
timeFrame: During the procedure
measure: Blood loss
timeFrame: During the procedure
Secondary outcomes:
measure: Pain score
timeFrame: Postoperative 1st and 2nd days
measure: Drain amount
timeFrame: Postoperative 1st and 2nd days
Other outcomes:
Locations:
city: Incheon
country: Korea, Republic of
facility: Inha University Hospital
Study officials:
References:
Clinical trial NCT00224601: CHROENDOHNPCC: Early Detection of Pre-cancer Lesions in Adults With Hereditary Nonpolyposis Colorectal Cancer Syndrome
Official title: Early Detection of Pre-cancer Lesions in Adults With Hereditary Nonpolyposis Colorectal Cancer (HNPCC) Syndrome: Assessment of Coloscopy With Chromoscopy Benefit
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Colorectal Neoplasms, Hereditary Nonpolyposis
Keywords: Colorectal cancer
HNPCC
Diagnosis
Coloscopy
Chromoscopy
Indigo carmine
Colorectal Neoplasms
Hereditary Nonpolyposis
Lead sponsor: Assistance Publique - Hôpitaux de Paris
Sponsor class: OTHER
First posted: 2005-09-23
Enrollment: 80
Sex: ALL
Minimum age (years): 25
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The aim of the study is to test the hypothesis that a chromoscopy colonoscopy is able to increase by 50 % the number of pre-cancer lesions or early cancer detected in patients with HNPCC syndrome, compared to a routine colonoscopy without chromoscopy.

Detailed description: Patient with HNPCC syndrome confirmed by a mutation (MLH1, MSH2, MHS1) are involved in the study. Patient have 2 colonoscopy back to back. The second coloscopy is associated to chromoscopy with carmin indigo. Endoscopist are randomised for the colonoscopy with chromoscopy and are un-awarded of the result of the first colonoscopy. Histopathology of the polyp are noted. The follow up were 1 month.

Eligibility criteria: Inclusion Criteria:

* Patients with MLH1, MSH2 or MSH6 mutation.
* Patients concerned by early detection colonoscopy.

Exclusion Criteria:

* Coloscopy of tracking since less 1an
* occlusive Syndrome contra-indicating the preparation for a total coloscopies
* Colectomies
* medical Conditions or serious illnesses contra-indicating a coloscopy of screening
* pregnant Woman or nursing
* Anomaly of coagulation contra-indicating the realization of biopsies and/or the exeresis of the lesion colorectal

Primary outcomes:
measure: Number of pre-cancer lesions or early cancer detected.
timeFrame: during the procedure
Secondary outcomes:
measure: Anatomopathologic criteria (size of lesions, …).
timeFrame: during the procedure
Other outcomes:
Locations:
city: Paris
country: France
facility: Hopital Europeen Georges Pompidou
state: Ile de France
Study officials:
affiliation: Assistance Publique - Hôpitaux de Paris
name: Christophe CELLIER, Pr,MD,PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Mention JJ, Ben Ahmed M, Begue B, Barbe U, Verkarre V, Asnafi V, Colombel JF, Cugnenc PH, Ruemmele FM, McIntyre E, Brousse N, Cellier C, Cerf-Bensussan N. Interleukin 15: a key to disrupted intraepithelial lymphocyte homeostasis and lymphomagenesis in celiac disease. Gastroenterology. 2003 Sep;125(3):730-45. doi: 10.1016/s0016-5085(03)01047-3.
Clinical trial NCT06749301: Repeatability and Reproducibility of the ADC Map in Head and Neck Cancer. Prospective Multicenter Study
Official title: Repeatability and Reproducibility of the ADC Map in Head and Neck Cancer. Prospective Multicenter Study
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Head and Neck Carcinoma
Lead sponsor: Regina Elena Cancer Institute
Sponsor class: OTHER
First posted: 2024-12-27
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with SCC of the head and neck who, according to standard procedures, will have to undergo an MRI examination fordiagnostic purposes.

Patients must also meet the inclusion criteria

Brief summary: Evaluation of the repeatability and reproducibility of ADC maps in both primary and non-primary lesions lymph nodes in patients with head and neck cancer, using an acquisition protocol Standardized DWI

Detailed description: DWI imaging consists of a spin-echo echo-planar sequence (SE-EPI) that will be acquired with 1.5 T or 3 T tomographs according to the equipment of the individual centers involved, setting the acquisition parameters after the administration of any contrast medium.

Eligibility criteria: Inclusion Criteria:

* age over 18 years;
* primary squamous cell carcinoma (SCC) of the hypopharynx, oropharynx, or oral cavity; confirmed by histology;
* a lesion visible on at least three consecutive DWI images, with a minimum diameter of 2 cm;
* specific written informed consent;

Exclusion Criteria:

* incomplete acquisition of DWI images;
* presence of artifacts that do not allow quantitative analysis of DWI images;
* performance status 2 or more according to Zubrod.

Primary outcomes:
measure: Evaluation of the short-term repeatability of ADC maps in both primary and nodal lesions in patients with squamous cell carcinomas (SCC) of the head and neck
timeFrame: 18 months
Secondary outcomes:
Other outcomes:
Locations:
city: Rome
country: Italy
facility: IRCCS National Cancer Institute "regina Elena"
Study officials:
References:
Clinical trial NCT05598801: A Single-center, Prospective, Clinical Study of VersaWrap Utilization in the Hand
Official title: A Single-center, Prospective, Clinical Study of VersaWrap Utilization in the Hand
Study type: OBSERVATIONAL
Overall status: ENROLLING_BY_INVITATION
Conditions: Tendon Repair
Fracture Repair
Tenolysis
Lead sponsor: Research Source
Sponsor class: NETWORK
First posted: 2022-10-28
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients who meet the following inclusion criteria and none of the exclusion criteria will be enrolled in the study. A patient is considered enrolled upon placement of the VersaWrap during the surgical procedure. If the surgeon decides intra-operatively not to utilize the VersaWrap, the patient will be considered a screen failure.

Brief summary: The purpose of this study is to evaluate the efficacy on the use of VersaWrap® in surgery of the hand/fingers, including tendon repair, fracture repair, or tenolysis of the hand/fingers. VersaWrap is designed to allow tendon gliding and to protect tendon gliding postoperatively

Detailed description: This is a prospective, post-market, observational, single center study evaluating the use of VersaWrap. Patients identified by the Investigator in his practice as needing surgery of the hand/fingers and meeting all the inclusion and none of the exclusion. Patients will consent to participating in the study, prior to any study procedures.

Eligibility criteria: Inclusion Criteria:

1. Patients aged 18-70 at the time of surgery
2. Patients undergoing hand/finger surgery, including tendon repair, fracture repair or tenolysis
3. Psychosocially, mentally and physically able to fully comply with this protocol including adhering to follow-up schedule, study requirements with a signed informed consent with a study collaborator present at the time of signing to ensure compliance.

Exclusion Criteria:

1. Non-English speaking
2. Known allergy or sensitivity to citrate, alginate or hyaluronate
3. Pregnant or breastfeeding
4. Currently a prisoner
5. Patient has any condition, that in the opinion of the Investigator, would prohibit the patient from complying with the protocol

Primary outcomes:
measure: Number of participants diagnosed with post-operative tenolysis
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Austin
country: United States
facility: Austin Hand Group
state: Texas
Study officials:
References:
Clinical trial NCT02685501: Menorrhagia, Dysmenorrhea and Iron Deficiency Among Young Women Soldiers and Effect on Activity
Official title: Menorrhagia, Dysmenorrhea and Iron Deficiency Among Young Women Soldiers
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Menorrhagia
Dysmenorrhea
Iron Deficiency Anemia
Lead sponsor: Hadassah Medical Organization
Sponsor class: OTHER
First posted: 2016-02-18
Enrollment: 800
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 25
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Women soldiers

Brief summary: As combat women soldiers are required to more intensive daily activity the investigators believe that the impact of menorrhagia, dysmenorrhea and its clinical consequence (as characterized by, anemia iron deficiency and reduced quality of life)) on personal performance will be more significant in combat women soldiers compared to non-combat women soldiers. Using cohorts from the same environment will enable the investigators to better study the effect of menorrhagia and dysmenorrhea eliminating other uncontrolled factors, such as nutrition. The study does not include any intervention.


Eligibility criteria: Inclusion Criteria:

* Women soldiers in the participating units

Exclusion Criteria:

* Lack of consent

Primary outcomes:
measure: Menorrhagia and dysmenorrhea
timeFrame: one year
Secondary outcomes:
measure: Iron deficiency
timeFrame: one year
Other outcomes:
Locations:
city: Jerusalem
country: Israel
facility: Hadassah Medical Organization
city: Jerusalem
country: Israel
facility: Hadassah Medical Organization
Study officials:
References:
Clinical trial NCT02451501: Influence of Body Posture on Pulmonary Aerosol Deposition
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Lead sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Sponsor class: OTHER
First posted: 2015-05-22
Enrollment: 6
Sex: MALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To compare deposition in two different positions.


Eligibility criteria: Inclusion Criteria:

* Free of respiratory disease

Exclusion Criteria:

* Smokers

Primary outcomes:
measure: Lung deposition by scintigraphy
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Brussels
country: Belgium
facility: Cliniques universitaires Saint-Luc
Study officials:
References:
citation: Reychler G, San Miguel-Pagola M, Aubriot AS, Herrero-Cortina B, Lecocq V, Hesse M, Liistro G, Jamar F. Targeted Lung Deposition From Nebulization Is Not Improved in the Lateral Decubitus Position in Healthy Volunteers. Respir Care. 2019 Dec;64(12):1537-1544. doi: 10.4187/respcare.06978. Epub 2019 Sep 10.
Clinical trial NCT04931901: Paired Assessment of Two Electromyographic Neuromuscular Monitors: Stimpod NMX450X Versus Datex-Ohmeda E-NMT
Official title: Paired Assessment of Two Electromyographic Neuromuscular Monitors: Stimpod NMX450X Versus Datex-Ohmeda E-NMT
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Neuromuscular Manifestations
Lead sponsor: Universitair Ziekenhuis Brussel
Sponsor class: OTHER
First posted: 2021-06-18
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Randomization per dominant and nondominant hand. So that there is an even share of number of patients with Stimpod NMX450X on dominant hand and Datex-Ohmeda E-NMT.
Primary purpose: SUPPORTIVE_CARE

Brief summary: After anesthesia is induced, 2 EMG TOFF devices will be placed on the patients arms, one on the right arm, the other on the left. There will be a randomization per dominant hand and nondominant hand for the placing of the devices. The devices are the Stimpod NMX450X and the Datex-Ohmeda E-NMT.


Eligibility criteria: Inclusion Criteria:

* Adult patients (18 years old and above)
* undergoing General Anaesthesia for noncardiac surgery requiring the use of a neuromuscular blocking agent.

Exclusion Criteria:

* Use of different types of neuromuscular blocking agents for the same patient within the same surgical procedure.
* Known Neuromuscular diseases/syndromes judged to condition accurate neuromuscular monitoring.
* Known acute or chronic hepatic disease.

Primary outcomes:
measure: TOF-ratio (percentage)
timeFrame: Up until 120 minutes
Secondary outcomes:
measure: TOF-count (absolute number)
timeFrame: Up until 120 minutes.
Other outcomes:
Locations:
city: Jette
country: Belgium
facility: UZ Brussel
state: Brussel
Study officials:
References:
Clinical trial NCT00301301: A Retrospective Review of Gemcitabine, Methylprednisolone Cisplatin (GEM-P) With or Without Rituximab in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Non-Hodgkins Lymphoma
Lead sponsor: Royal Marsden NHS Foundation Trust
Sponsor class: OTHER
First posted: 2006-03-10
Enrollment: 39
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 39 participants aged over 18 with histological diagnosid of diffuse large B cell lymphoma and written informed consent. Patients who have received Gemcitabine-cisplatin, methylprednisolone (GEM-P) as per standard unit guidelines with or without Rituximab for relapsed/refractory DLBCL.

Brief summary: There has been considerable international /national interest in the GEM-P regimen for treatment of patients with relapsed/refractory lymphoma. Currently, there is no accepted standard therapy for these patients. Since the publication of our experience with this regimen (Study with CCR ethics number 1857 closed to recruitment in July 2003:Ng M, Waters J, Cunningham D et al, Br J Cancer 2005;92:1352-7), we have treated relapsed/refractory lymphoma patients with this regimen and would like to undertake a retrospective review of a sub-group of these patients with diffuse large B cell lymphoma (DLBCL).

Patients treated with GEM-P with or without Rituximab prior to March 2005 for refractory/relapsed DLBCL will be included in the analysis. Accrual of eligible patients currently under follow-up will be performed in clinic at the time of next appointment.

All patients accrued will give informed consent for retrospective case note review, after discussion with a study investigator and after receiving a study information sheet. All eligible patients identified from the pharmacy database, and will be consented at the time of the next clinic appointment, if they are agreeable for the retrospective case note review.


Eligibility criteria: Inclusion Criteria:

- a) Age over 18 b) Histological diagnosis of diffuse large B cell lymphoma c) Patients who have received Gemcitabine-cisplatin, methylprednisolone (GEM-P) as per standard unit guidelines with or without Rituximab for relapsed/refractory DLBCL.

d) Informed written consent

Exclusion Criteria:

* a) Medical or psychiatric conditions that compromise the patient's ability to give informed consent b) HIV positive or AIDS related lymphoma

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Sutton
country: United Kingdom
facility: Royal Marsden NHS trust
state: Surrey
Study officials:
affiliation: Royal Marsden NHS Foundation Trust
name: David Cunningham, FRCP
role: PRINCIPAL_INVESTIGATOR
References: